MARKET

ADMS

ADMS

Adamas Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.88
-0.02
-0.34%
After Hours: 5.85 -0.03 -0.51% 18:31 01/17 EST
OPEN
5.94
PREV CLOSE
5.90
HIGH
6.06
LOW
5.80
VOLUME
450.85K
TURNOVER
--
52 WEEK HIGH
12.57
52 WEEK LOW
3.350
MARKET CAP
163.80M
P/E (TTM)
-1.4588
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADMS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ADMS News

  • SHAREHOLDER ALERT: ADMS FSCT EXC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  • ACCESSWIRE.2d ago
  • ADMS EQUITY NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.; Important Deadline in Case - ADMS
  • ACCESSWIRE.2d ago
  • CLASS ACTION UPDATE for ADMS, MMSI and BZUN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  • ACCESSWIRE.2d ago
  • INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines
  • ACCESSWIRE.2d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About ADMS

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
More

Webull offers Adamas Pharmaceuticals Inc (ADMS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.